7 stories mentioning COSM
Every FINWIRES story that references COSM, newest first.
Cosmos Health (COSM) said Friday its wholly-owned subsidiary Cana Laboratories has received new contract manufacturing orders from Nassington and Verisfield.The orders comprise a combined 253,657 units covering a range of medicines and pharmaceutical products, according to a statement.Price: $0.21, Change: $+0.01, Percent Change: +2.91%
Cosmos Health (COSM) said late Thursday it has signed a non-binding letter of intent to acquire Doc Pharma, a fully licensed GMP pharmaceutical manufacturer.The proposed acquisition is part of its plan to build an end-to-end healthcare platform, the company said.Doc Pharma has an asset base of about $24 million and generated some $6.7 million in three-year average annual revenue, it added.Price: $0.21, Change: $-0.02, Percent Change: -10.00%
Cosmos Health's (COSM) Cana Laboratories signed a three-year contract manufacturing agreement with Verisfield for 3.9 million units of VASCLOR GEST progesterone pessaries.The deal adds a new customer and expands Cana's women's-health manufacturing portfolio. Cosmos said Wednesday in a statement.Financial terms weren't disclosed.Price: $0.23, Change: $+0.01, Percent Change: +2.87%
Cosmos Health (COSM) said its Cana Laboratories unit acquired an international patent application from Cloudpharm and has begun seeking national and regional protection in key markets.The technology combines early-stage discovery methods with advanced pharmaceutical development approaches, the company said Monday in a statement.Cana also plans to expand investment in nanotechnology-based platforms for pharmaceutical, nutraceutical, over-the-counter and specialized healthcare products.The company said the project will integrate the newly acquired IP with Cana's European manufacturing capabilities.Price: $0.22, Change: $-0.03, Percent Change: -10.53%
Cosmos Health (COSM) said Monday that it has completed the first phase execution of its Liv18 liver health supplement ahead of schedule.Production of Liv18 is expected to commence this month, with initial market rollout to follow shortly thereafter, the company said.Cosmos said that based on planned investments in advertising, customer acquisition, and business development, along with early US commercial traction from its other products, Liv18 is expected to generate over $5 million in annual revenue, with gross margins of about 75%.Shares of the company were down more than 6% in Monday's trading.Price: $0.38, Change: $-0.03, Percent Change: -6.47%
Cosmos Health (COSM) said Friday it will launch its Cur18 curcumin supplement in the US market during Q2.The supplement is designed to overcome "poor bioavailability," a common issue with conventional curcumin formulations that do not dissolve easily in the digestive system, the healthcare company said.Cur18 uses a whole-spectrum extract that offers 39 times higher bioavailability than standard 95% curcuminoid extracts, based on a pharmacokinetic study, the company said.The study also showed that the formulation achieves 49.5 times higher total curcumin exposure, while separate clinical data showed meaningful improvements in knee pain for osteoarthritis patients, the company added.Price: $0.39, Change: $-0.02, Percent Change: -3.94%
Cosmos Health (COSM) received a new purchase order for 60,000 units of its Sky Premium Life products from Pharmalink under their exclusive distribution agreement for the United Arab Emirates market.This is the third straight order from Pharmalink, bringing cumulative orders since June 2024 to 270,000 units, Cosmos Health said Monday in a statement.Price: $0.31, Change: $+0.02, Percent Change: +6.14%